Palantir is gaining significant traction in the tech world with its AI-driven services, experiencing a dramatic stock ...

If you purchased or acquired securities in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA Biosciences, the biotech has agreed to sell the deals to an investment ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...